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Abstract PTEN is an important tumor suppressor gene that
antagonizes the oncogenic PI3K/AKT signaling pathway and
has functions in the nucleus for maintaining genome integrity.
Although PTEN inactivation bymutation is infrequent in breast
cancer, transcript and protein levels are deficient in >25 % of
cases. The E3 ubiquitin ligase NEDD4 (also known as
NEDD4-1) has been reported to negatively regulate PTEN pro-
tein levels through poly-ubiquitination and proteolysis in carci-
nomas of the prostate, lung, and bladder, but its effect on PTEN
in the breast has not been studied extensively. To investigate
whether NEDD4 contributes to low PTEN levels in human
breast cancer, we analyzed the expression of these proteins by
immunohistochemistry across a large Swedish cohort of breast
tumor specimens, and their transcript expression levels by mi-
croarrays. For both NEDD4 and PTEN, their transcript expres-
sion was significantly correlated to their protein expression.
However, comparing NEDD4 expression to PTEN expression,
either no association or a positive correlation was observed at
the protein and transcript levels. This unexpected observation
was further corroborated in two independent breast cancer co-
horts from The Netherlands Cancer Institute and The Cancer
Genome Atlas. Our results suggest that NEDD4 is not respon-
sible for the frequent down-regulation of the PTEN protein in
human breast carcinoma.
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Introduction
PTEN is a phosphatase that plays an important role in tumor
suppression by negatively regulating the oncogenic phos-
phatidylinositol 3-kinase (PI3K) pathway, as well as through
functions in the nucleus that contribute to maintenance of
genomic integrity [1]. Germline mutations of PTEN are found
in patients with PTEN hamartoma tumor syndrome and are
associated with an increased risk for breast, thyroid, and en-
dometrial cancer [2–4]. Moreover, somatic loss-of-function
mutations of PTEN are estimated to be present in 30 % of
cancer and are found across the entire spectrum of tumor types
[5–7]. The PTEN/PI3K pathway is one of the key pathways
deregulated in breast cancer. PIK3CA, which encodes the
p110-alpha catalytic subunit of PI3K, has activating mutations
in one-third of breast tumors, and although mutation rate of
PTEN is less than 5 % [8], PTEN expression is found to be
greatly diminished in at least 25% of breast tumors and in near
mutual exclusivity to PIK3CA mutation [9, 10]. The mecha-
nisms by which PTEN is down-regulated is poorly delineated
in breast cancer, but mutations, copy number loss, rearrange-
ments, epigenetic silencing, as well as post-translational reg-
ulation may contribute [9–13]. Of note, PTEN loss is frequent
within the poor-prognosis basal-like molecular subtype of
breast cancer [13].
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Recently, Wang et al. reported that NEDD4 (neural precur-
sor cell expressed, developmentally down-regulated 4, E3
ubiquitin protein ligase; also known as NEDD4-1) is an E3
ubiquitin ligase of PTEN and catalyzes poly-ubiquitination of
PTEN in cells leading to proteolysis of the PTEN protein,
thereby negatively regulating PTEN abundance [14].
Furthermore, in their analysis of mouse prostate and human
bladder cancer samples, high expression of NEDD4 was in-
versely correlated to PTEN protein levels but not PTEN
mRNA levels, suggesting that NEDD4 plays a proto-
oncogenic role in tumorigenesis and cancer development via
post-translational suppression of PTEN [14]. Negative regu-
lation of PTEN by NEDD4-mediated poly-ubiquitination has
since been reported to be involved in several biological and
pathological processes, such as axon branching [15, 16], T-
cell activation [17], keloid formation [18], and insulin-
mediated glucose metabolism [19]. Inverse relationships be-
tween the expression of NEDD4 and PTEN have also been
observed in human non-small cell lung carcinomas [20] and
colon cancer [21].
However, the regulation of PTEN by NEDD4 may be mi-
croenvironment and/or cell-type specific. For example,
Trotman et al. found that in addition to catalyzing poly-
ubiquitination of PTEN, NEDD4 is also responsible for
PTENmono-ubiquitination that leads to PTEN nuclear import
and protection from proteasomal degradation, making the role
of NEDD4 in regulation of PTEN stability subtle and complex
[22]. Moreover, some studies have called into question the
interaction between NEDD4 and PTEN. For example, no dis-
cernible effect on Pten stability, subcellular localization, or
downstream targets was observed in two separate Nedd4
knock-out mouse models [23]. Furthermore, Maddika et al.
failed to reproduce the functional interaction between NEDD4
and PTEN, and instead found that WWP2, another E3 ubiq-
uitin ligase within the NEDD4-like protein family, mediated
poly-ubiquitination of PTEN [24]. A third group has also
failed to demonstrate that PTEN is a substrate of Nedd4, and
rather found that PTEN regulated Nedd4 by modulating
mTORC1 activity [19]. Lastly, in gastric carcinoma, no rela-
tionship was observed between NEDD4 and PTEN expres-
sion [25], and in colorectal cancer cell lines and biopsies,
NEDD4 modulation and expression level were not associated
to the levels of PTEN [26].
NEDD4 and its potential role in PTEN regulation in breast
cancer have not been studied. To reveal the pattern of expres-
sion of NEDD4 in human breast cancer, and to investigate
whether NEDD4-mediated PTEN degradation is a factor that
contributes to the frequent loss of PTEN protein, we analyzed
NEDD4 and PTEN expression at the protein and mRNA
levels in a large cohort of Swedish breast tumors, and verified
our findings in two independent breast cancer cohorts from
The Netherlands Cancer Institute (NKI) and The Cancer
Genome Atlas (TCGA) (Table 1).
Materials and Methods
Breast Cancer Cohorts
Clinical and demographic information is provided for all co-
horts in Table 1. For the Swedish cohort, 132 formalin-fixed
paraffin-embedded (FFPE) tissue microarray (TMA) tumor
specimens, arrayed in triplicates, were studied for NEDD4
protein expression by IHC, of which 123 had matched
PTEN IHC scores previously evaluated [9, 27]. These 123
samples were analyzed for correlation between PTEN and
NEDD4 protein levels. Correlation between the PTEN protein
and NEDD4 mRNA levels, and correlation between PTEN
mRNA and NEDD4 mRNA levels were analyzed in a subset
of 105 samples with both PTEN IHC status and microarray
gene expression data [27] (NCBI Gene Expression Omnibus
accession GSE5325). Correlation between NEDD4 protein
and NEDD4 mRNA levels was performed in a subset of 42
samples with NEDD4 IHC and microarray data. For the NKI
cohort, gene expression microarray data from 295 tumor sam-
ples was analyzed for correlation between gene expression
levels of PTEN and NEDD4 [28, 29]. Tissue microarrays con-
taining these 295 NKI cases were stained for PTEN protein, of
which 267 samples could be evaluated, and thereafter were
analyzed for correlations between PTEN IHC scores and
PTEN or NEDD4 mRNA expression levels. For TCGA co-
hort, level 3 IlluminaHiSeq_RNASeqV2 gene expression data
for 970 primary breast tumor samples was used, as well as
PTEN protein expression status for 407 cases derived from a
reverse phase protein arrays platform. All TCGA data were
downloaded from the TCGA data portal (https://tcga-data.nci.
nih.gov/tcga/, downloaded on January 20, 2014). The study
was approved by the Lund University Hospital ethics
committee (LU240-01 and 2009/658), waiving the
requirement for informed consent for the study, and all
experimental protocols were performed in accordance with
approved guidelines.
Immunohistochemistry
The rabbit polyclonal anti-NEDD4 WW2 domain antibody
#07–049 (EMD Millipore, Darmstadt, Germany), previously
validated to be specific for NEDD4 [14], was used for IHC.
The staining was done using an Autostainer Plus instrument
and EnVision Plus system (Dako Denmark A/S, Glostrup,
Denmark) following manufacturer’s recommended protocol.
Antigen retrieval was performed using Dako Targeted
Retrieval Buffer pH 6.0 at 98 °C for 20 min, and the primary
antibody was used at 1:500 dilution with 30 min incubation
time at room temperature. The stained specimens were
scanned using a MIRAX MIDI slide scanner (Carl Zeiss
AG, Oberkochen, Germany) and viewed with Pannoramic
Viewer v1.15.3 (3DHISTECH, Budapest, Hungary). Semi-
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quantitative scoring was done according to the Dako system
0–3 scoring scale, where scores of 0 were given to tissues with
no NEDD4 staining, 1+ to weak NEDD4 staining, 2+ to in-
termediate NEDD4 staining, and 3+ to strong NEDD4 stain-
ing (Fig. 1). The IHC scores of 0 and 1+ were then combined
and categorized as NEDD4-negative, and scores of 2+ and 3+
were categorized as NEDD4-positive. PTEN IHC results for
the Swedish cohort were reported previously [9, 27]. PTEN
IHC was performed on the NKI TMAs using methods previ-
ously described [13].
Statistical Analysis
The chi-squared test was used to test the significance level of
correlations between the NEDD4 protein and different breast
cancer biomarkers. The Wilcoxon rank-sum test was used for
correlation between PTEN and NEDD4 protein levels. The
Student’s t-test was used for correlations between the PTEN/
NEDD4 protein and PTEN/NEDD4 mRNA levels. The
Pearson’s correlation test was used for correlations between
PTEN and NEDD4 mRNA levels from gene expression data
and RNA-seq data. All tests were two-tailed, and P < 0.05was
considered significant. All statistical analyses were performed
with R version 3.1.0 (http://www.r-project.org).
Results and Discussion
Immunohistochemical (IHC) staining was performed for 132
formalin-fixed paraffin-embedded (FFPE) breast tumor spec-
imens (Swedish cohort) using an antibody previously reported
to be specific to NEDD4 [14] (see Methods; Fig. 1).
Consistent with previous studies in other tissues [14],
NEDD4 protein was predominantly cytoplasmic in breast can-
cer cells (Fig. 1). Among the 132 stained samples, 60 (45 %)
had zero or weak NEDD4 protein staining (classified as
NEDD4-negative), whereas 72 (55 %) had intermediate to
strong expression (NEDD4-positive). NEDD4 protein expres-
sion was positively correlated to estrogen receptor status (ER;
P = 0.0017), but not associated to the other clinical variables
Table 1 Clinical demographics of the breast cancer patients
Swedish Cohort NKI cohort TCGA cohort
With protein data With mRNA data
n = 186 (%) n = 123 (%) n = 105 (%) n = 295 (%) n = 970 (%)
Median age at diagnosis (y/o) 62 (range, 26–80) 64 (range, 31–80) 61 (range, 26–77) 44 (range, 26–53) 59 (range, 26–90)
Median tumor size (mm) 25 (range, 2–55) 25 (range, 10–55) 27 (range, 2–50) 20 (range, 2–50) NA (NA)
Estrogen receptor
Positive 121 (65) 85 (69) 55 (52) 214 (73) 716 (74)
Negative 59 (32) 35 (28) 47 (45) 72 (24) 210 (22)
Unknown 6 (3) 3 (2) 3 (3) 9 (3) 44 (5)
Progesterone receptor
Positive 78 (42) 55 (45) 35 (33) 185 (63) 622 (64)
Negative 98 (53) 64 (52) 62 (59) 101 (34) 301 (31)
Unknown 10 (5) 4 (3) 8 (8) 9 (3) 47 (5)
HER2
Positive 27 (15) 16 (13) 18 (17) 56 (19) 148 (15)
Negative 113 (61) 84 (68) 55 (52) 217 (74) 496 (51)
Equivocal NA (NA) NA (NA) NA (NA) NA (NA) 156 (16)
Unknown 46 (25) 23 (19) 32 (30) 22 (7) 170 (18)
Nottingham histological grade
1 3 (2) 1 (1) 3 (3) 60 (20) NA (NA)
2 47 (25) 15 (12) 37 (35) 99 (34) NA (NA)
3 37 (20) 14 (11) 28 (27) 136 (46) NA (NA)
Unknown 99 (53) 93 (75) 37 (35) 0 (0) NA (NA)
Lymph node
Positive 118 (63) 79 (64) 65 (62) 144 (49) 411 (42)
Negative 68 (37) 44 (36) 40 (38) 151 (51) 397 (41)
Unknown 0 (0) 0 (0) 0 (0) 0 (0) 162 (17)
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progesterone receptor (PR; P = 0.12), human epidermal
growth factor receptor 2 (HER2; P = 0.12), Nottingham
Histologic Grade (P = 0.57), and Ki-67 (P = 0.40) (Table 2).
Microarray gene expression data were available for 42 of the
132 cases from a previous study [27]. Using this data, we
found NEDD4 protein levels to be significantly correlated to
NEDD4 mRNA expression level (P = 0.04) (Fig. 2a),
supporting the specificity of the antibody and also indicating
that NEDD4 mRNA may be an appropriate surrogate for
NEDD4 protein levels in breast cancer.
PTEN protein expression was previously determined by
IHC for 123 of the 132 cases [9]. We tested whether
NEDD4 protein levels were negatively associated to PTEN
protein levels, however no correlation was seen in this
Swedish breast cancer material (P = 0.12; Fig. 2b). This was
inconsistent with the inverse correlation between the two pro-
teins observed in a mouse prostate cancer model [14] and in
lung cancers [20]. In fact, in our Swedish cohort the correla-
tion trended positively, with 77 % of cases being PTEN-
positive within the NEDD4-positive group compared to
64 % being PTEN-positive in the NEDD4-negative group
(Fig. 2b).
In human bladder carcinoma, Wang et al. reported NEDD4
mRNA expression and PTEN mRNA expression to be uncor-
related, but that NEDD4 mRNA levels were inversely corre-
lated to PTEN protein levels [14]. To investigate if it is also the
case in breast tumors, we next considered the transcript levels
of these genes using the GSE5325 microarray dataset of 105
breast tumors previously utilized to develop a gene expression
signature for PTEN-loss [27]. In contrast to bladder cancer, we
found no correlation between NEDD4mRNA and PTEN pro-
tein expression (P = 0.73; Fig. 2c). PTEN mRNA, however,
was highly correlated to PTEN protein (P < 0.001; Fig. 2d),
which has been previously reported [27]. Unexpectedly, we
found PTEN mRNA levels to be significantly positively cor-
related to NEDD4 protein expression (N = 42, P = 0.02;
Fig. 2e) as well as to NEDD4 mRNA levels (N = 105,
P = 0.03; Fig. 2f).
To validate these findings, two independent large-scale
breast cancer cohorts from the NKI and TCGAwere studied.
The NKI cohort contained 295 breast tumor samples with
microarray gene expression data [28, 29]. Tissue microarray
sections were obtained and immunostained for PTEN protein,
of which 267 cases were evaluable. Similar to the Swedish
cohort, we found no correlation between NEDD4mRNA and
PTEN protein (P = 0.39; Fig. 3a). The strong positive corre-
lation between PTEN mRNA and PTEN protein (P < 0.001;
Fig. 3b), as well as the association of our previously published
PTEN-loss signature [27] with loss of PTEN protein
Fig. 1 NEDD4 immunohistochemistry. 132 breast tumor tissue
microarray specimens were immunohistochemically stained with anti-
NEDD4 antibody. Shown are representative examples of tumors with
NEDD4 IHC scores of a 0, b 1+, c 2+, and d 3+. Scores 0/1+ were
categorized NEDD4-negative, and 2+/3+ as NEDD4-positive. NEDD4
protein was expressed predominantly in the cytoplasm regardless of the
staining intensity
Table 2 Correlations of NEDD4 protein with biomarkers in the
Swedish cohort
NEDD4- NEDD4+ N χ2 P
Estrogen receptor
Positive 33 57 129 0.0017
Negative 26 13
Progesterone receptor
Positive 21 36 128 0.12
Negative 36 35
HER2
Positive 11 6 108 0.12
Negative 40 51
Nottingham histological grade
1 0 1 32 0.4
2 9 7
3 10 5
Ki-67
Positive 2 7 37 0.57
Negative 9 19
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(P = 0.003; data not shown), were confirmed in this indepen-
dent dataset. Moreover, the positive association between
NEDD4 mRNA and PTEN mRNA found in our Swedish
cohort was also validated in the NKI patient material
(N = 295, P < 0.001; Fig. 3c).
These associations were further corroborated in the TCGA
breast carcinoma cohort containing RNA-sequencing (RNA-
seq) gene expression profiles of primary breast tumors from
970 patients, of which 407 also had available PTEN protein
expression data derived from reverse phase protein arrays
[10]. In this large cohort the correlation between NEDD4
mRNA and PTEN protein was also significantly positive
(P < 0.001; Fig. 4a). Additionally, PTEN mRNA and PTEN
protein levels were positively correlated (P < 0.001; Fig. 4b),
as observed in the Swedish and NKI cohorts. Lastly, the
positive correlation between NEDD4 mRNA and PTEN
mRNA levels was also confirmed in the TCGA dataset
(P < 0.001; Fig. 4c).
In conclusion, our study investigated whether PTEN was
associated to NEDD4 in three large independent breast cancer
sample cohorts. Contrary to reports in some other cancer
forms, no inverse relationship was seen betweenNEDD4 tran-
script and PTEN protein levels. Rather, there was no correla-
tion between NEDD4 protein and PTEN protein, and the cor-
relation between NEDD4 mRNA/protein and PTEN mRNA
was significantly positive. NEDD4-mediated poly-
ubiquitination of PTEN may be an important mechanism that
contributes to PTEN protein loss in bladder cancer [14] and
non-small cell lung carcinoma [20]; whereas the results in
gastric and colorectal cancers have been discrepant [25, 26].
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Fig. 3 PTEN mRNA/protein levels and NEDD4 mRNA levels in the
NKI cohort. PTEN IHC scores were not associated to a NEDD4
mRNA levels (N = 267, P = 0.39), but were significantly correlated to
b PTENmRNA levels (N = 267, P < 0.001). c PTENmRNA andNEDD4
mRNA levels were also significantly correlated (N = 295, R = 0.19,
P < 0.001)
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Interestingly, in ovarian cancer HeLa cells, PTEN has also
been reported to negatively regulate NEDD4 expression via
the PI3K/AKT pathway, forming a potential negative feed-
back loop [30]. Our present study does not support NEDD4
as a major negative regulator of PTEN levels in human breast
cancer. Additional studies are necessary to better delineate the
underlying mechanisms of PTEN loss in this poor-prognosis
subgroup.
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